Linifanib
- Generic Name
- Linifanib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H18FN5O
- CAS Number
- 796967-16-3
- Unique Ingredient Identifier
- CO93X137CW
- Background
Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels that supply the tumor with oxygen and nutrients and by inhibiting key angiogenic signaling pathways. Linifanib is intended for the treatment of hematologic malignancies and the solid tumors.
- Indication
Investigated for use/treatment in leukemia (myeloid), myelodysplastic syndrome, and solid tumors.
- Associated Conditions
- -
- Associated Therapies
- -
Aethlon Medical, Inc. (NASDAQ:AEMD) Q3 2023 Earnings Call Transcript
Aethlon Medical discussed Q3 2023 financials, highlighting a $17.5M cash balance and a $2.85M net loss. They're advancing the Hemopurifier in oncology trials, selected NAMSA as CRO, and hired Dr. Lee Arnold as Chief Scientific Officer. A subsidiary in Australia aims to leverage favorable R&D incentives.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath